West-Ward Pharmaceuticals
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$13.2M
Doctors Paid
4,119
Transactions
9,223
2018 Total
$9.8M
Payment Breakdown by Category
Research$12.0M (90.5%)
Consulting$883,751 (6.7%)
Food & Beverage$126,873 (1.0%)
Travel$115,169 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.0M | 539 | 90.5% |
| Consulting Fee | $883,751 | 67 | 6.7% |
| Food and Beverage | $126,873 | 8,492 | 1.0% |
| Travel and Lodging | $115,169 | 43 | 0.9% |
| Honoraria | $81,125 | 17 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $56,500 | 13 | 0.4% |
| Education | $369.20 | 52 | 0.0% |
Payments by Type
Research
$12.0M
539 transactions
General
$1.3M
8,684 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study | $5.1M | 1 | 225 |
| Buprenorphine Transdermal Pivotal Study | $1.5M | 0 | 1 |
| Buprenorphine Transdermal Sensitization Study | $612,507 | 0 | 1 |
| Balsalazide Fed Pivotal Study | $397,842 | 0 | 1 |
| Opioid PMR Study | $349,273 | 57 | 191 |
| Erlotinib Tablets, 100 mg, Pivotal Study | $278,630 | 0 | 1 |
| Erlotinib Tablets, 150 mg, Pivotal Study | $274,525 | 0 | 1 |
| Bexarotene Pivotal Fed Study | $263,286 | 0 | 1 |
| Droxidopa Capsules, 300 mg, Pivotal Fed Study | $210,844 | 0 | 1 |
| Droxidopa Capsules, 300 mg, Pivotal Fasted Study | $210,844 | 0 | 1 |
| Buprenorphine TD Pilot Study | $195,750 | 0 | 1 |
| Deferiprone Fed Pivotal Study | $189,073 | 0 | 1 |
| Ambrisentan Fed Pivotal Study | $188,108 | 0 | 1 |
| Deferiprone Fasted Pivotal Study | $182,409 | 0 | 1 |
| Bexarotene Fed Pivotal Study | $178,777 | 0 | 1 |
| Ambrisentan Fasted Pivotal Study | $170,487 | 0 | 1 |
| Triazolam Fed Pivotal Study | $166,123 | 0 | 1 |
| Triazolam Fasted Pivotal Study | $166,123 | 0 | 1 |
| Trientine Fasted Pivotal Study | $166,112 | 0 | 1 |
| Morphine Pediatric Study | $151,533 | 0 | 29 |
| Apremilast Fed Pilot Study | $144,531 | 0 | 1 |
| Apremilast Fasted Pilot Study | $144,256 | 0 | 1 |
| Phase 4 Open Label Pediatric Study to Determine Pharmacokinetics of Phenylephrine | $115,312 | 0 | 27 |
| Bexarotene Fed Pilot Study | $111,966 | 0 | 1 |
| Phytonadione Fasted Pilot Study | $105,278 | 0 | 1 |
| Buprenorphine Transdermal Pilot Study | $80,867 | 0 | 1 |
| Levomilnacipran Fasted Pivotal Study | $74,652 | 0 | 1 |
| Mirabegron Fasted Pilot Study | $74,617 | 0 | 1 |
| Phytonadione Fed Pilot Study | $42,240 | 0 | 1 |
| Levomilnacipran Fasted Pilot Study | $31,392 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 165
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Rutkumar Jani, Md, MD | Family Medicine | Columbia, SC | $10.39 | $0 |
| Dr. Huong Phan, Md, MD | Internal Medicine | Columbia, SC | $10.39 | $0 |
| Dr. Ann Kulik, M.d, M.D | Family Medicine | Greensboro, NC | $10.39 | $0 |
| Dr. Erik Crook, M.d, M.D | Internal Medicine | Columbia, SC | $10.39 | $0 |
| James Altieri, Md, MD | Family Medicine | Columbia, SC | $10.39 | $0 |
| Stephen Youmans, Md, MD | Family Medicine | Aiken, SC | $10.39 | $0 |
| Dr. Ruben Mayer, Md, MD | Internal Medicine | Columbia, SC | $10.39 | $0 |
| Dr. Eva Imperial, Md, MD | Family Medicine | Mooresville, NC | $10.38 | $0 |
| Dr. Lora Meadows, Md, MD | Internal Medicine | Hilton Head, SC | $10.38 | $0 |
| Unknown Provider | — | — | $10.38 | $0 |
| John Nicholson, Md, MD | Internal Medicine | Statesville, NC | $10.38 | $0 |
| Robert Ruggiero, M.d, M.D | Specialist | Malvern, PA | $10.37 | $0 |
| Jonathan Moore, M.d, M.D | Student in an Organized Health Care Education/Training Program | Mobile, AL | $10.36 | $0 |
| Garnett Lowry, M.d, M.D | Family Medicine | Raeford, NC | $10.36 | $0 |
| Andrea Pincham Benton, Md, MD | Internal Medicine | Hoover, AL | $10.35 | $0 |
| Dr. Noor Bunney, Md, MD | Internal Medicine | Troy, MI | $10.35 | $0 |
| Willie Williams, M.d, M.D | Internal Medicine | Birmingham, AL | $10.34 | $0 |
| Dr. James Langan, Md, MD | Internal Medicine | Birmingham, AL | $10.34 | $0 |
| Cristina Perez Gomez, Md, MD | Internal Medicine | Crest Hill, IL | $10.33 | $0 |
Ad
Top Products
- Fluticasone Salmeterol $5.1M
- Buprenorphine $2.9M
Associated Products (18)
- Erlotinib $704,945
- Bexarotene $554,029
- Droxidopa $421,688
- Balsalazide $397,842
- Deferiprone $371,482
- Ambrisentan $358,596
- Oncology TA $357,897
- Triazolam $332,246
- Buprenorphine & Naloxone $293,256
- Apremilast $288,786
- Oxycodone hydrochloride ER tablet $190,979
- Trientine $166,112
- Phytonadione $147,519
- Levomilnacipran $146,948
- Morphine Sulfate ER tablets $126,410
- Oxymorphone hydrochloride ER tablet $79,659
- Azelastine / fluticasone $23,074
- Imatinib $14,750
Payment Categories
- Food & Beverage $126,873
- Consulting $883,751
- Travel & Lodging $115,169
- Research $12.0M
About West-Ward Pharmaceuticals
West-Ward Pharmaceuticals has made $13.2M in payments to 4,119 healthcare providers, recorded across 9,223 transactions in the CMS Open Payments database. In 2018, the company paid $9.8M. The top product by payment volume is Fluticasone Salmeterol ($5.1M).
Payments were distributed across 80 medical specialties. The top specialty by payment amount is Emergency Medicine ($158,524 to 28 doctors).
Payment categories include: Food & Beverage ($126,873), Consulting ($883,751), Research ($12.0M), Travel & Lodging ($115,169).
West-Ward Pharmaceuticals is associated with 18 products in the CMS Open Payments database, including Erlotinib, Bexarotene, and Droxidopa.